Plus Therapeutics, Inc.

PSTV

US72941H5090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 23/05/2024 am IST			5-day change	1st Jan Change
2.18 ^USD	+2.35%		-6.03%	+24.56%

15/05	Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024
09/05	Transcript : Plus Therapeutics, Inc. - Special Call

Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC

May 09, 2024

On May 9, 2024, Plus Therapeutics, Inc., closed the transaction.

Latest news about Plus Therapeutics, Inc.

Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024	16/05
Transcript : Plus Therapeutics, Inc. - Special Call	09/05
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC	09/05	CI
Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC	05/05	CI
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	22/04	MT
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	22/04	CI
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	25/03	CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	11/03	CI
Transcript : Plus Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	06/03
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
North American Morning Briefing : S&P 500 Futures -2-	05/03	DJ
Transcript : Plus Therapeutics, Inc. - Special Call	20/11
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	20/11	CI
Top Premarket Gainers	03/11	MT
Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation	03/11	DJ
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	01/23/01	CI
Transcript : Plus Therapeutics, Inc., Q3 2023 Earnings Call, Oct 31, 2023	01/23/01
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	01/23/01	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/23/01	CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.	31/23/31	CI
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	10/23/10	CI
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	09/23/09	MT
Sector Update: Health Care Stocks Slipping Friday Afternoon	08/23/08	MT
Sector Update: Health Care	08/23/08	MT
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	08/23/08	MT

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Plus Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.18 USD

Average target price

16.5 USD

Spread / Average Target

+656.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PLUS THERAPEUTICS, INC.	+24.56%	17.13M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.93%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research